GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have changed the landscape of medical weight management. But science doesn’t stop here. A new wave of dual-mechanism and combination therapies is emerging, offering even greater results for people struggling with obesity.
What Are Combination Therapies?
Combination medications target multiple pathways in the body, including hormones that control appetite, metabolism, and energy use. By working together, these drugs may achieve deeper, more sustained weight loss than GLP-1 medications alone.
Exciting Developments on the Horizon
- CagriSema (Cagrilintide + Semaglutide)
- A combination of GLP-1 and amylin analogs.
- Phase III trials show nearly 20% average body weight loss in 68 weeks.
- Offers improved appetite control and better satiety compared to GLP-1 alone.
- Amycretin
- Targets both amylin and GLP-1 pathways.
- Early data suggest it may lead to faster weight loss while improving blood sugar control.
- Pemvidutide
- A dual GLP-1/glucagon receptor agonist.
- Promising results include weight loss plus potential improvements in liver health (NASH).
Why Combination Therapies Matter
Just as cardiology evolved from single medications to advanced combinations, obesity medicine is moving forward with sophisticated, multi-pathway approaches. For patients who don’t respond fully to first-line GLP-1s, these new therapies may provide another level of hope.
Achieve’s Advantage
At Achieve Health and Weight Loss, we are not a “pill mill.” We function as a subspecialty medical practice in weight management, just like a cardiologist focuses on the heart. Our concierge-level program ensures:
- Careful selection of the right therapy for each individual.
- Continuous monitoring and adjustment to maximize safety and effectiveness.
- Monthly communication with your primary care provider upon request.
- Guidance on nutrition, lifestyle, and behavioral support alongside medications.
Looking Ahead
The future of weight management is bright, with new combination therapies set to offer even better outcomes. At Achieve, we stay ahead of the science, so you can stay ahead of obesity.
